<DOC>
	<DOCNO>NCT00916227</DOCNO>
	<brief_summary>This Phase 1 study patient low intermediate-1 risk myelodysplastic syndrome ( MDS ) receive investigational study drug ARRY-614 . This study 2 part . In first part , patient receive increase dos study drug , give either food without food , order achieve high dose study drug possible cause unacceptable side effect . Approximately 60 patient US enrol Part 1 ( Completed ) . In second part study , patient receive best dose study drug , give either food without food , determine first part study follow see side effect effectiveness study drug , , treat cancer . Approximately 40 patient US enrol Part 2 ( Completed ) .</brief_summary>
	<brief_title>A Study ARRY-614 Patients With Low Intermediate-1 Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 1 Part 2 ) : Diagnosis MDS bone marrow biopsy . International Prognostic Scoring System ( IPSS ) score low intermediate1 risk MDS . May receive prior therapy MDS . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 . Adequate liver renal function . Additional criterion exist . Key Exclusion Criteria ( Part 1 Part 2 ) : History bone marrow transplant . Concomitant malignancies previous malignancy less 2year diseasefree interval time enrollment . Treatment investigational medicinal product expect clear first dose study drug demonstrate late side effect . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis C and/or active hepatitis B . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Low Intermediate-1 Risk Myelodysplastic Syndrome</keyword>
</DOC>